Available IPD datapackage for study 'A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Doses of BIIB014 Administered Orally in Subjects With Early Parkinson's Disease'

The main purpose of this study is to determine the safety of BIIB014 and how well BIIB014 is
tolerated when given at different doses to patients with early-stage Parkinson's Disease.

This study will also explore:

- How BIIB014 is affected when given to patients with early-stage Parkinson's Disease
(this will be done by measuring the levels of BIIB014 in the blood at several different
times during the study), and

- The activity of BIIB014 when given to early Parkinson's patients (this will be done by
performing different Parkinson's Disease assessments and other tests during the study).

Patients who enter this study will be randomly assigned to receive either BIIB014 or a
placebo but because the study is blinded, neither they nor their study doctor will know which
study treatment they are taking.